At the 2024 American Thoracic Society (ATS) International Conference, Stephanie A. Christenson, MD, MAS, observed significant progress in chronic obstructive pulmonary disease (COPD) research, particularly in therapeutic advancements. Key highlights included trials focusing on biologics targeting type 2 inflammation, such as therapies addressing thymic stromal lymphopoietin and phosphodiesterase 3/4 inhibitors. In addition, findings on beta-blockers emphasized their safety with selective targeting, albeit without significant exacerbation reduction.
The emerging landscape of COPD therapeutics hints at a transformative shift in the field, fueling optimism for future research endeavors and the prospect of precision medicine in COPD care. Overall, the conference underscored the potential for breakthroughs in understanding COPD biology and enhancing patient outcomes.
 "BCCI want Test specialists to play domestic cricket; Rohit, Virat, Bumrah to be exceptions")
